We would appreciate it if you could complete our website survey, open until 28 November 2025.
This item is authorised by the following title:
For a transitional provision relating to the repeal of this instrument, see section 38 of the National Health (Highly Specialised Drugs Program) Special Arrangement 2021 (PB 27 of 2021).
For a transitional provision relating to the repeal of this instrument, see section 38 of the National Health (Highly Specialised Drugs Program) Special Arrangement 2021 (PB 27 of 2021).